Detalhe da pesquisa
1.
Multiple myeloma.
Lancet
; 397(10272): 410-427, 2021 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33516340
2.
Myeloma patients' experiences of a supervised physical activity programme: a qualitative study.
Support Care Cancer
; 30(7): 6273-6286, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35467117
3.
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive).
Haematologica
; 106(10): 2694-2706, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33910333
4.
Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design.
Br J Cancer
; 123(2): 187-195, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32435057
5.
Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy.
Br J Haematol
; 191(2): 194-206, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32678948
6.
BCMA CARs in multiple myeloma: room for more?
Blood
; 137(21): 2859-2860, 2021 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34042980
7.
Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors.
Br J Haematol
; 196(3): e21-e26, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34632575
8.
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.
Br J Haematol
; 196(4): e33-e37, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34636043
9.
Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model.
Br J Haematol
; 172(1): 64-79, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26767468
10.
Development of antibody response to SARS-CoV-2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy.
Br J Haematol
; 194(5): 857-861, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34323287
11.
Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
Br J Haematol
; 174(6): 911-22, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27313079
12.
Response to 'Impact of immunosuppression on mortality in critically ill COVID-19 patients'.
Br J Haematol
; 191(3): 505-506, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33103782
13.
Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials.
Br J Haematol
; 185(2): 344-347, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29978458
14.
Clinical benefit of depth of response for relapsed/refractory multiple myeloma patients treated on clinical trials: retrospective analysis from two tertiary centres.
Br J Haematol
; 186(1): 162-165, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30592025
15.
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
Br J Haematol
; 185(5): 948-951, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30460696
16.
More convenient proteasome inhibition for improved outcomes.
Lancet Oncol
; 19(7): 856-858, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29866476
17.
Deep Learning Enables Spatial Mapping of the Mosaic Microenvironment of Myeloma Bone Marrow Trephine Biopsies.
Cancer Res
; 84(3): 493-508, 2024 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37963212
18.
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Lancet Rheumatol
; 6(6): e339-e351, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38734019
19.
A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors.
BMC Cancer
; 13: 31, 2013 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-23347597
20.
Improved response with post-ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma.
Br J Haematol
; 158(4): 499-505, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22712536